OBJECTIVE: The immediate overwhelming release of inflammatory mediators in septic shock is rapidly followed by strong anti-inflammatory responses inducing a state of immunosuppression. The patients who survive the initial hyper-inflammatory step of septic shock but subsequently die may be those who do not recover from immunosuppression. We assessed whether a low monocyte human leukocyte antigen-DR (mHLA-DR) expression, proposed as a marker of immunosuppression, is an independent predictor of mortality in patients who survived the initial 48 h of septic shock. DESIGN AND SETTING: Prospective observational study performed in two adult intensive care units at a university hospital. PATIENTS: 93 consecutive patients with septic shock. MEASUREMENTS AND RESULTS: At days 1-2, mHLA-DR values (determined by flow cytometry) were not significantly different between survivors and non-survivors. A sharp difference became highly significant at days 3-4 when survivors had increased their values, while non-survivors had not (43% vs. 18%, percentage of HLA-DR positive monocyte, p < 0.001). Multivariate logistic regression analysis revealed that low mHLA-DR (< 30%) at days 3-4 remained independently associated with mortality after adjustment for usual clinical confounders, adjusted odds ratio (CI): 6.48 (95% CI: 1.62-25.93). CONCLUSION: The present preliminary results show that mHLA-DR is an independent predictor of mortality in septic shock patients. Being a marker of immune failure, low mHLA-DR may provide a rationale for initiating therapy to reverse immunosuppression. After validation of the current results in multicenter studies, mHLA-DR may help to stratify patients when designing a mediator-directed therapy in a time-dependent manner.
OBJECTIVE: The immediate overwhelming release of inflammatory mediators in septic shock is rapidly followed by strong anti-inflammatory responses inducing a state of immunosuppression. The patients who survive the initial hyper-inflammatory step of septic shock but subsequently die may be those who do not recover from immunosuppression. We assessed whether a low monocyte human leukocyte antigen-DR (mHLA-DR) expression, proposed as a marker of immunosuppression, is an independent predictor of mortality in patients who survived the initial 48 h of septic shock. DESIGN AND SETTING: Prospective observational study performed in two adult intensive care units at a university hospital. PATIENTS: 93 consecutive patients with septic shock. MEASUREMENTS AND RESULTS: At days 1-2, mHLA-DR values (determined by flow cytometry) were not significantly different between survivors and non-survivors. A sharp difference became highly significant at days 3-4 when survivors had increased their values, while non-survivors had not (43% vs. 18%, percentage of HLA-DR positive monocyte, p < 0.001). Multivariate logistic regression analysis revealed that low mHLA-DR (< 30%) at days 3-4 remained independently associated with mortality after adjustment for usual clinical confounders, adjusted odds ratio (CI): 6.48 (95% CI: 1.62-25.93). CONCLUSION: The present preliminary results show that mHLA-DR is an independent predictor of mortality in septic shockpatients. Being a marker of immune failure, low mHLA-DR may provide a rationale for initiating therapy to reverse immunosuppression. After validation of the current results in multicenter studies, mHLA-DR may help to stratify patients when designing a mediator-directed therapy in a time-dependent manner.
Authors: Wolf-Dietrich Döcke; Conny Höflich; Kenneth A Davis; Karsten Röttgers; Christian Meisel; Paul Kiefer; Stefan U Weber; Monika Hedwig-Geissing; Ernst Kreuzfelder; Peter Tschentscher; Thomas Nebe; Andrea Engel; Guillaume Monneret; Andreas Spittler; Kathrin Schmolke; Petra Reinke; Hans-Dieter Volk; Dagmar Kunz Journal: Clin Chem Date: 2005-10-07 Impact factor: 8.327
Authors: M Ditschkowski; E Kreuzfelder; V Rebmann; S Ferencik; M Majetschak; E N Schmid; U Obertacke; H Hirche; U F Schade; H Grosse-Wilde Journal: Ann Surg Date: 1999-02 Impact factor: 12.969
Authors: J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher Journal: Crit Care Med Date: 1998-11 Impact factor: 7.598
Authors: Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze Journal: Microbiol Mol Biol Rev Date: 2012-03 Impact factor: 11.056
Authors: Kirstin Howell; Joseph Posluszny; Li K He; Andrea Szilagyi; John Halerz; Richard L Gamelli; Ravi Shankar; Kuzhali Muthu Journal: J Leukoc Biol Date: 2011-10-07 Impact factor: 4.962
Authors: Stephen Booth; Geraint D Florida-James; Brian K McFarlin; Guillaume Spielmann; Daniel P O'Connor; Richard J Simpson Journal: Eur J Appl Physiol Date: 2010-08-27 Impact factor: 3.078
Authors: Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz Journal: Neuro Oncol Date: 2010-02-23 Impact factor: 12.300
Authors: Mark W Hall; Susan M Geyer; Chao-Yu Guo; Angela Panoskaltsis-Mortari; Philippe Jouvet; Jill Ferdinands; David K Shay; Jyotsna Nateri; Kristin Greathouse; Ryan Sullivan; Tram Tran; Shannon Keisling; Adrienne G Randolph Journal: Crit Care Med Date: 2013-01 Impact factor: 7.598
Authors: Sally A Madsen-Bouterse; Roberto Romero; Adi L Tarca; Juan Pedro Kusanovic; Jimmy Espinoza; Chong Jai Kim; Jung-Sun Kim; Samuel S Edwin; Ricardo Gomez; Sorin Draghici Journal: Am J Reprod Immunol Date: 2010-01 Impact factor: 3.886